Estradiol Patch Shortage: Safe Alternatives and How to Choose the Right Estrogen Therapy
If you’ve recently been told your estradiol patch is out of stock or backordered, you’re not alone.
Ongoing supply disruptions are affecting several estradiol patch products, and many women are having trouble filling their prescriptions. This can be frustrating, especially if you have finally found a menopausal hormone therapy plan that works well for you.
If you’re navigating this, you may be wondering:
What should I do if my estradiol patch is unavailable — and are other options just as safe?
The good news is that you still have options.
This article walks through what’s happening and how to think about your options in a clear, evidence-based, and practical way.
Why Is There an Estradiol Patch Shortage?
The current estradiol patch shortage appears to be related to a combination of factors, including:
Increased demand for menopause care
Manufacturer-specific supply issues
Limited availability of certain brands, doses, or formulations
As more women seek effective, evidence-based treatment for menopause symptoms, demand for transdermal estradiol has increased. Unfortunately, supply has not always kept up.
For patients, this can feel stressful and discouraging. A medication shortage is not just an inconvenience when that medication is helping you sleep, function, and feel like yourself again.
Why Transdermal Estrogen Is Often Preferred?
Transdermal estrogen includes:
Patches
Gels
Sprays
These forms deliver estrogen through the skin and:
Bypass first-pass liver metabolism
Can provide more consistent hormone delivery for many patients
Have less impact on certain clotting factors
Because of this, transdermal estradiol is often preferred when we are trying to minimize clotting risk, especially in patients with certain risk factors.¹
That does not mean transdermal estrogen is the only appropriate option. It simply means the route of estrogen matters, and it should be considered as part of an individualized plan.
Important Update: It’s Not Just the Patch
While the shortage has primarily affected estradiol patches, the impact can feel broader for patients.
As patients and clinicians look for alternatives, other transdermal options such as gels and sprays may come up. These can be helpful options for some patients, but they are not always easy to access.
Many of the non-patch transdermal estrogen options do not have generic equivalents, and they can be significantly more expensive. Insurance coverage also varies, which means an option that works well medically may not be practical financially.
As a result:
These options may be harder to access
Costs may be higher
Insurance coverage may be limited or inconsistent
A lower-cost generic option may not be available
This means the issue is not always limited to finding “another patch.” Sometimes the challenge is finding a safe, effective, and affordable option that is actually available.
Estradiol Patch vs Pill: What’s the Difference?
The main difference between transdermal estradiol and oral estradiol is how the body processes them.
Transdermal Estradiol: Patch, Gel, or Spray
Absorbed through the skin
Bypasses the liver
Lower impact on certain clotting factors
Oral Estradiol: Pill
Absorbed through the digestive system
Undergoes first-pass metabolism in the liver
Can influence liver-produced proteins, including some clotting factors
These differences help guide clinical decision-making. They do not mean one option is automatically right for every person.
How Do We Think About Safety?
Rather than labeling one option as “safe” and another as “unsafe,” it is more accurate to consider individual risk.
Transdermal estrogen is often preferred when minimizing clotting risk is a priority
Oral estradiol may be appropriate for many women, particularly those at lower baseline risk
Oral estrogen is associated with increased VTE risk compared with some non-oral routes, but the individual level of risk depends heavily on age, medical history, and other risk factors.¹
The goal is not to categorically avoid one route of estrogen. The goal is to choose the therapy that best fits the individual patient.
A Common Misunderstanding: Estradiol vs Ethinyl Estradiol
A frequent source of confusion is the assumption that all estrogen formulations carry the same risk.
They do not.
Menopausal hormone therapy typically uses estradiol, which is chemically the same form of estrogen the body naturally produces
Combined oral contraceptives often use ethinyl estradiol, a synthetic estrogen with a stronger hepatic effect
Ethinyl estradiol has a stronger hepatic effect than estradiol used in menopausal hormone therapy. This means risks from combined oral contraceptives should not be automatically applied to menopausal hormone therapy.²
These medications are different. They are used for different reasons, often at different doses, and in different patient populations.
This distinction matters because many women have heard broad warnings about “estrogen” without being told which type of estrogen, what dose, what route, or what patient population those warnings apply to.
What Are Your Options Right Now?
If your estradiol patch is unavailable, options may include:
1. Alternative Transdermal Options
Estradiol gels
Estradiol sprays
Considerations:
May be more difficult to access during current shortages
Often do not have generic options
May have higher out-of-pocket costs
May not be covered the same way by insurance
For some patients, these can be excellent options. For others, cost or availability may make them difficult to use consistently.
2. Oral Estradiol
Oral estradiol may be an option for some patients.
Potential benefits:
Widely available
Effective for vasomotor symptom relief
Often easier to obtain than certain patch formulations
Considerations:
Not preferred for some higher-risk patients
Should be chosen based on individual medical history and risk profile
For many women, oral estradiol can be a reasonable option when transdermal estrogen is unavailable or not affordable. This decision should be made with your clinician, not out of panic at the pharmacy counter.
3. Adjusting Within Available Options
Sometimes the solution is not a completely different medication, but an adjustment within available options.
This may include:
Switching patch brands, if available
Adjusting dose
Using a temporary transition plan to maintain symptom control
The key is to make changes intentionally and safely.
Choosing the Right Option in Real Life
The best treatment plan depends not only on clinical evidence, but also on practical considerations.
Key factors include:
Medical history and risk profile
Symptom severity
Patient preference
Medication availability
Cost and insurance coverage
During the current estradiol patch shortage, treatment decisions often require flexibility.
This is not about choosing an ideal option in theory. It is about choosing a safe, effective, and sustainable option in real life.
Access matters. A medication may be clinically appropriate, but if it is unavailable, unaffordable, or not covered by insurance, it may not be sustainable for the patient.
What to Avoid
If your medication is unavailable, avoid:
Stopping estrogen abruptly without checking with your clinician
Rationing doses
Cutting or changing patches without guidance
Switching medications without clinical support
Switching to compounded hormone products without a careful discussion of quality, dosing consistency, safety, and whether an FDA-approved option is available
These approaches can lead to symptom recurrence, unnecessary instability, or avoidable safety concerns.
You do not have to figure this out alone, and you do not have to simply suffer through symptoms because your usual patch is unavailable.
Our Approach
At Illumination Women’s Health, we take an individualized approach to menopausal hormone therapy.
We work with patients to navigate:
Patch vs pill vs gel decisions
Safety considerations
Medication shortages
Insurance and cost barriers
Symptom control and quality of life
Our goal is to create a treatment plan that reflects both the evidence and the reality of your life.
Most importantly, we want you to feel heard, informed, and supported in the decision-making process.
The Bottom Line
The estradiol patch shortage is changing how menopause care is being delivered, but it does not eliminate safe and effective options.
Transdermal estrogen remains preferred in certain higher-risk situations
Other transdermal options may be limited or more expensive
Oral estradiol remains an appropriate option for some patients
Access, affordability, and consistency matter
Even the most appropriate therapy is not helpful if it is unavailable or unaffordable.
The goal is to identify a plan that is:
Safe
Effective
Sustainable
Care at Illumination Women’s Health
We provide evidence-based menopausal hormone therapy, offering:
Telehealth across Idaho and Montana
If you are navigating the estradiol patch shortage, we can help you adjust your treatment plan with clarity and confidence.
Schedule a menopause consultation.
References
American College of Obstetricians and Gynecologists. Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism. Committee Opinion No. 556. Obstet Gynecol. 2013;121:887–890.
Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. BMJ. 2008;336:1227–1231.
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas. 2018;115:1–5.
The Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause. 2022;29(7):767–794.
